Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) announced the opening of its Alkermes Inspiration Grants program, starting from May 1, 2023. The program, now in its seventh year, will allocate up to $500,000 in grants to support nonprofit organizations addressing issues related to addiction, serious mental illness, and cancer. CEO Richard Pops emphasized the importance of empowering nonprofits tackling complex health challenges. The grants will focus on programs that assist populations affected by alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma, or ovarian cancer. Eligible U.S. 501(c)(3) nonprofits can submit applications until June 1, 2023. For more details and application guidelines, visit Alkermes Inspiration Grants.

Positive

• Alkermes is committing up to $500,000 in grants to address critical health challenges.
• The program aims to support historically under-resourced or underrepresented populations.

Negative

• None.

– Application Period to Begin on May 1, 2023 –

DUBLIN, April 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants^® program beginning on May 1, 2023. Now in its seventh year, this competitive grant program will provide up to a total of $500,000 in grants to assist nonprofit organizations in their work to address the needs of people living with addiction, serious mental illness or cancer.  

"We see the gravity of unmet need in our communities to address stigmatized and increasingly complex health challenges — yet we remain hopeful because of the passion, energy and holistic problem-solving put forth by nonprofit organizations working on the front lines," said Richard Pops, Chief Executive Officer of Alkermes. "Through the Alkermes Inspiration Grants program, we have a unique opportunity to listen to, understand and empower organizations seeking to complement medicine and clinical care, and support populations who have faced longstanding and widespread health disparities."

This year's submissions will be evaluated based on the set of criteria outlined in the request for proposals, with a focus on people affected by alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma or ovarian cancer. Proposals should include clearly defined needs, objectives, activity format, mode of delivery and intended audience, and be relevant to historically under-resourced or underrepresented populations. Alkermes seeks to support programs that have a broad reach within the U.S. and potential to lead to sustained impact. Grant recipients will be selected by a committee that includes senior leaders from Alkermes and individuals from outside the company chosen to represent the perspectives of people with lived experience, caregivers and patient advocates.

Eligible U.S. 501(c)(3) nonprofit organizations may submit a grant application between May 1, 2023 and June 1, 2023. For more information on the Alkermes Inspiration Grants program, including submission instructions, additional eligibility guidelines, evaluation criteria and a link to the application portal, please visit https://www.alkermes.com/responsibility/alkermes-inspiration-grants-2023.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

ALKERMES INSPIRATION GRANTS^® is a registered service mark of Alkermes, Inc.

Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media:      Gretchen Murphy,  +1 781 609 6419

View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-announces-application-period-for-2023-alkermes-inspiration-grants-program-to-support-innovative-initiatives-focused-on-people-affected-by-addiction-serious-mental-illness-or-cancer-301801167.html

SOURCE Alkermes plc

FAQ

When does the application period for the Alkermes Inspiration Grants program open?

The application period opens on May 1, 2023.

What is the total amount available for the Alkermes Inspiration Grants?

Up to $500,000 is available for the Alkermes Inspiration Grants program.

Who can apply for the Alkermes Inspiration Grants?

Eligible U.S. 501(c)(3) nonprofit organizations can apply.

What are the focus areas of the Alkermes Inspiration Grants?

The grants focus on addiction, serious mental illness, and cancer, particularly alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma, and ovarian cancer.

What is the deadline for submitting applications for the Alkermes Inspiration Grants?

The deadline for submitting applications is June 1, 2023.